Immunogenicity of a truncated enterovirus 71 VP1 protein fused to a Newcastle disease virus nucleocapsid protein fragment in mice

Acta Virologica

Volumn 55, Issue 3, 2011, Pages 227-233

  Ch'ng, W C ^a   Saw, W T ^a   Yusoff, K ^a   Shafee, N ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Enterovirus 71; Immunogenicity; Recombinant VP1 protein

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; PROTEIN VP1; RECOMBINANT NUCLEOCAPSID VP1 PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; ENTEROVIRUS INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; SPLEEN CELL;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BLOTTING, WESTERN; CAPSID PROTEINS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; RECOMBINANT PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

ANIMALIA; HUMAN ENTEROVIRUS 71; MIRIDAE; MUS; NEWCASTLE DISEASE VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 84855926589     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2011_03_227     Document Type: Article

References (32)

1. Abzug MJ (2009): Enterovirus 71: emergence of the new poliomyelitis. South Afr. J. Epidemiol. Infect. 24, 5-8
2. Bergmann C, Van Hemmen JL, Segel LA (2001): Th1 or Th2: how an appropriate T helper response can be made. Bull. Math. Biol. 63, 405-430.
3. Cafruny WA, Haven TR, Lawson SR, Wong GH, Rowland RR (1997): Inhibition of virus-induced age-dependent poliomyelitis by interferon-gamma. Antiviral Res. 36, 1-9.
4. Chang LY (2008): Enterovirus 71 in Taiwan. Pediatr. Neonatol. 49, 103-112.
5. Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, Chiang YP, Chiang BL, Lee CY, Huang LM (2006): Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr. Res. 60, 466-471.
6. Chang LY, Shih SR, Huang LM, Lin TY (2007): Enterovirus 71 encephalitis. In Fong, IW, Alibeck K (Eds): New and Evolving Infections of the 21st Century. Springer, New York, pp. 295-325.
7. Chen HF, Chang MH, Chiang BL, Jeng ST (2006): Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24, 2944-2951.
8. Del Prete G, and Romagnani S (1994): The role of TH1 and TH2 subsets in human infectious diseases. Trends Microbiol. 2, 4-6.
9. Ding NZ, Wang XM, Sun SW, Song Q, Li SN, He CQ (2009): Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. Virus Res. 145, 157-161.
10. Feng CY, Li QT, Zhang XY, Dong K, Hu BY, Guo XK (2009): Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against leptospira. Braz. J. Med. Biol. Res. 42, 796-803.
11. Foo DG, Alonso S, Chow VT, Poh CL (2007a): Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 9, 1299-1306.
12. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL (2007b): Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 125, 61-68.
13. Goldsby RA, Kindt TJ, Osborne BA, Kuby J (2003): Immunology. W.H. Freeman and Company, New York
14. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR (1999): An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N. Engl. J. Med. 341, 929-935.
15. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF (1999): Neurologic complications in children with enterovirus 71 infection. N. Engl. J. Med. 341, 936-942.
16. Kho CL, Tan WS, Yusoff K (2001): Production of the nucleocapsid protein of Newcastle disease virus in Escherichia coli and its assembly into ring-and nucleocapsid-like particles. J. Microbiol. 39, 293-299.
17. King AMQ, Brown F, Christian P, Hovi T, Hyypia T, Knowles NJ, Lemon SM, Minor PD, Palmenberg AC, Skern T, Stanway G (2000): Picornaviridae. In MHV Van Regenmortel, CM Fauquet, DHL Bishop, CH Calisher, EB Carsten, MK Estes, SM Lemon, J Maniloff, MA Mayo, DJ McGeoch, CR Pringle, RB Wickner (Eds): Virus Yaxonomy: the Classification and Nomenclature of Viruses. The Seventh Report of the International Committee for the Taxonomy of Viruses. Academic Press, New York, pp. 657-673.
18. Makkay AM, Krell PJ, Nagy E (1999): Antibody detection-based differential ELISA for NDV-infected or vaccinated chickens versus NDV HN-subunit vaccinated chickens. Vet. Microbiol. 66, 209-222.
19. McMinn PC (2002): An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26, 91-107.
20. Melnick JL (1996): Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In BN Fields, DM Knipe, PM Howley, RM Chanlock, JL Melnick, TP Monath, B Roizman, E Straus (Eds): Fields Virology. Lippincott-Raven Publishers, Philadelphia, pp. 655-712.
21. Mountcastle WE, Compans RW, Caliguiri LA, Choppin PW (1970): Nucleocapsid protein subunits of simian virus 5, Newcastle disease virus, and Sendai virus. J. Virol. 6, 677-684.
22. Oberste MS, Maher K, Kilpatrick DR, Pallansch MA (1999): Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J. Virol. 73, 1941-1948.
23. Rabu A, Tan WS, Kho CL, Omar AR, Yusoff K (2002): Chimeric Newcastle disease virus nucleocapsid with parts of viral hemagglutinin-neuraminidase and fusion proteins. Acta Virol. 46, 211-217.
24. Rotbart HA, O'Connell JF, McKinlay MA (1998): Treatment of human enterovirus infections. Antiviral Res. 38, 1-14.
25. Rueckert RR (1990): Picornaviruses and their replication. In BN Fields, and DM Knipe (Eds): Virology. Raven Press, New York, pp. 507-548.
26. Schmidt NJ, Lennette EH, Ho HH (1974): An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129, 304-349.
27. Shih SR, Li YS, Chiou CC, Suen PC, Lin TY, Chang LY, Huang YC, Tsao KC, Ning HC, Wu TZ, Chan EC (2000): Expression of capsid protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection. J. Med. Virol. 61, 228-234.
28. Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K (2006): Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J. Med. Virol. 78, 1096-1104.
29. Tung WS, Bakar SA, Sekawi Z, Rosli R (2007): DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet. Vaccines Ther. 5, 6.
30. Wood P (2006): Understanding Immunology. Benjamin Cummings. New York.
31. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS (2001): Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20, 895-904.
32. Yusoff K, Tan WS (2001): Newcastle disease virus: macromolecules and opportunities. Avian Pathol. 30, 439-455.